TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546124

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Fascia Dry needling Technique
Description: Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Trigger Point Dry Needling Technique
Description: Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises.
Study: NCT05526417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Receive prehabilitation physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Attend telemedicine visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Attend telemedicine visits
Study: NCT06233812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple interrupted suturing technique
Description: Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple interrupted suturing technique
Description: Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running suturing technique
Description: Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Running suturing technique
Description: Both simple interrupted and running epidermal sutures are considered acceptable, appropriate techniques for FTSG placement. Therefore, this study would be important in determining whether running sutures, the more efficient method, are non-inferior to simple interrupted sutures.
Study: NCT05379491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 L PEG + linaclotide
Description: Participants take a linaclotide capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another linaclotide capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 L PEG + placebo
Description: Participants take a placebo capsule on the day before colonoscopy at least 30 minutes before the first meal (if this is impossible, take the capsule as early as possible on that day). Participants take 1 L polyethylene glycol electrolyte solution within 1 hour from 8 p.m the night before the examination and take another placebo capsule and 2 L polyethylene glycol electrolyte solution 4 hours before the colonoscopy.
Study: NCT06269822

Intervention type: DIAGNOSTIC_TEST
Intervention: Sympathetic skin response, heart rate variability test, quantitative EEG
Description: Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Sympathetic skin response, heart rate variability test, quantitative EEG
Description: Sympathetic skin test (electrodermal activity) to test for sympathetic function Heart rate variability test to assess cardiovagal function Quantitative EEG to quantitatively assessing the brain function using fast fourier transform technique
Study: NCT05603338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LSG with omental band
Description: LSG with omental band

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG
Description: just to do sleeve gastrectomy
Study: NCT05925686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol.
Description: Orally single dose administration of Tramadol 75 mg for ultra-rapid metabolizers and 100 mg for extensive and poor metabolizers.
Study: NCT06184854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-Enhanced Training Models
Description: 3D-enhanced Jenga polo model for task 1 and 3D-enhanced suturing model for task 2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard 3D LapPass Training Models
Description: Standard 3D LapPass polo model for task 1 and standard 3D LapPass model for task 2
Study: NCT06071624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4CAR
Description: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Study: NCT06343103

Intervention type: OTHER
Group type: OTHER
Intervention: Workers exposed
Description: Workers exposed to cytotoxic agents

Intervention type: OTHER
Group type: OTHER
Intervention: Workers not exposed
Description: Workers not exposed to cytotoxic agents
Study: NCT05093218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: branch chain amino acid
Description: • Branch chain amino acid at a dose of approxiametely 0.35g/kg will be supplemented in two divided doses group for a period of 12 weeks.For the sake of administration, it will be prescribed as per the following weight band categories: \<5kg 2 gm 5-10kg 4 gm 10-20kg 8 gm 20-40kg 12 gm 40-60kg 24 gm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will have the similar colour, taste and consistency. Both groups will be given the same dose.
Study: NCT04497727

Intervention type: OTHER
Intervention: Gene Expression
Description: Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
Study: NCT06113692

Intervention type: BIOLOGICAL
Intervention: mRNA-1273
Description: intramuscular injection

Intervention type: BIOLOGICAL
Intervention: mRNA-1273
Description: intramuscular injection
Study: NCT05641363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: ketorolac tromethamine, an NSAID belonging to a group of non-opioid analgesics that inhibit the synthesis of prostaglandins and thromboxanes with strong analgesic and anti-inflammatory properties. It is the only non-opioid parenteral non-sedating analgesic available for use to treat acute pain in the emergency department.
Study: NCT04702724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (sounds)
Description: I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
Study: NCT04798391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Steroids and analgesics
Study: NCT05210452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular stem cells
Description: Cultured autologous follicular stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of alopecia according to the clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of alopecia according to the clinical protocols
Study: NCT05426057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Mental Health
Description: eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
Study: NCT06160414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive Metformin orally, after fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive Metformin orally, after fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive Rosuvastatin orally, after fasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive Rosuvastatin orally, after fasting.
Study: NCT06082557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T60c injection
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion.
Study: NCT06160414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Participants will receive ALXN2080 orally, after fasting.
Study: NCT06355479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OsrHSA
Description: Recombinant Human Serum Albumin from Oryza Sativa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasbumin®-20
Description: Albumin (Human) 20%, USP
Study: NCT05715476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarian surgery
Description: The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarian surgery
Description: The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarian surgery
Description: The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
Study: NCT06212050

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: TAVI in patients with severe BAV stenosis using ACURATE neo2
Study: NCT06447324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fender Mate matrix system
Description: Matrix Systems used for Restoration of Class II Cavities in Primary Molars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-band matrix
Description: Matrix Systems used for Restoration of Class II Cavities in Primary Molars
Study: NCT06207422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity training program
Description: A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity training program
Description: A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
Study: NCT06091189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relevant Trier Social Stressor Test (TSST)
Description: The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relevant Trier Social Stressor Test (TSST)
Description: The Relevant TSST condition is a behavioral intervention that catalyzes an internalized stress response in the presence of a relevant social identity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: The initial drink in the alcohol condition will contain 0.3 g/kg (males) or 0.2 g/kg (females) of 80-proof ethanol, adjusted for body weight, and subsequent drinks will contain 0.1 g/kg of ethanol. None of the control (placebo) drinks will contain ethanol.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Trier Social Stressor Test (TSST)
Description: The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Trier Social Stressor Test (TSST)
Description: The Placebo TSST is an established behavioral intervention that does not prompt significant stress responses.
Study: NCT06228950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
Study: NCT06113861

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold
Description: Test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold
Description: Test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold
Description: Test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantiferon Gold
Description: Test for TB infection

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV serology
Description: Test for HIV infection

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV serology
Description: Test for HIV infection
Study: NCT06091189

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Beverage
Description: Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Beverage
Description: Placebo drinks will not contain ethanol; Drinks given to participants in the placebo beverage condition will contain a mixer that does not contain ethanol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Irrelevant Trier Social Stressor Test (TSST)
Description: The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Irrelevant Trier Social Stressor Test (TSST)
Description: The Irrelevant TSST condition is a behavioral intervention that functions as an alternative comparative condition, given no internalized stress response is expected in the presence of an irrelevant social identity.
Study: NCT06113861

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV serology
Description: Test for HIV infection

Intervention type: DIAGNOSTIC_TEST
Intervention: HIV serology
Description: Test for HIV infection